Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2015
Summary
Global Markets Direct’s, ‘Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2015’, provides an overview of the Idiopathic Pulmonary Fibrosis’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Idiopathic Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Pulmonary Fibrosis and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Idiopathic Pulmonary Fibrosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Idiopathic Pulmonary Fibrosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Idiopathic Pulmonary Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Idiopathic Pulmonary Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Idiopathic Pulmonary Fibrosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Introduction
- Global Markets Direct Report Coverage
- Idiopathic Pulmonary Fibrosis Overview
- Therapeutics Development
- Pipeline Products for Idiopathic Pulmonary Fibrosis - Overview
- Pipeline Products for Idiopathic Pulmonary Fibrosis - Comparative Analysis
- Idiopathic Pulmonary Fibrosis - Therapeutics under Development by Companies
- Idiopathic Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes
- Idiopathic Pulmonary Fibrosis - Pipeline Products Glance
- Clinical Stage Products
- Early Stage Products
- Unknown Stage Products
- Idiopathic Pulmonary Fibrosis - Products under Development by Companies
- Idiopathic Pulmonary Fibrosis - Products under Investigation by Universities/Institutes
- Idiopathic Pulmonary Fibrosis - Companies Involved in Therapeutics Development
- AdAlta Pty Ltd.
- Aeolus Pharmaceuticals, Inc.
- Afferent Pharmaceuticals, Inc.
- AnaMar AB
- Biogen, Inc.
- Bioneer Corporation
- BiOrion Technologies B.V.
- Bristol-Myers Squibb Company
- Carolus Therapeutics, Inc.
- Celgene Corporation
- Chong Kun Dang Pharmaceutical Corp.
- Compugen Ltd.
- F. Hoffmann-La Roche Ltd.
- FibroGen, Inc.
- Galapagos NV
- GenKyoTex S.A.
- Gilead Sciences, Inc.
- Global Blood Therapeutics, Inc.
- HanAll Biopharma Co., Ltd.
- HEC Pharm Co., Ltd.
- Histocell S.L.
- iBio, Inc.
- ImmuneWorks, LLC
- Inventiva SAS
- Isarna Therapeutics GmbH
- Kadmon Corporation, LLC
- Kasiak Research Private Limited
- Kyorin Pharmaceutical Co., Ltd.
- LTT Bio-Pharma Co., Ltd.
- MedImmune, LLC
- Moerae Matrix, Inc.
- MorphoSys AG
- MSM Protein Technologies, Inc.
- Pacific Therapeutics Ltd.
- Pharmaxis Limited
- Progenra, Inc.
- Promedior, Inc.
- ProMetic Life Sciences Inc.
- Pulmatrix, Inc.
- Respira Therapeutics, Inc.
- Rhizen Pharmaceuticals SA
- Ribomic Inc.
- Sanofi
- Teva Pharmaceutical Industries Limited
- Yuhan Corporation
- Idiopathic Pulmonary Fibrosis - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- (pentoxifylline + acetylcysteine) - Drug Profile
- AEOL-10150 - Drug Profile
- AF-219 - Drug Profile
- AM-0010 - Drug Profile
- AMAP-102 - Drug Profile
- Antibodies to Inhibit LPA1 for Idiopathic Pulmonary Fibrosis - Drug Profile
- Antisense RNAi Oligonucleotide for COPD and IPF - Drug Profile
- Antisense RNAi Oligonucleotides for Idiopathic Pulmonary Fibrosis - Drug Profile
- BG-00011 - Drug Profile
- BMS-986020 - Drug Profile
- BOT-191 - Drug Profile
- CC-539 - Drug Profile
- CC-90001 - Drug Profile
- CGEN-25009 - Drug Profile
- CKD-942 - Drug Profile
- CMYJH-01 - Drug Profile
- CT-2009 - Drug Profile
- D-9030 - Drug Profile
- Drug to Inhibit Galectin-3 for Fibrosis - Drug Profile
- FG-3019 - Drug Profile
- GBT-1118 - Drug Profile
- GBT-440 - Drug Profile
- GKT-831 - Drug Profile
- GLPG-1690 - Drug Profile
- HC-016 - Drug Profile
- HEC-00000585 - Drug Profile
- HL-156FIB - Drug Profile
- HR-017 - Drug Profile
- IBIOCFB-03 - Drug Profile
- ICG-001 - Drug Profile
- ISTH-0047 - Drug Profile
- IVA-337 - Drug Profile
- IW-001 - Drug Profile
- KBP-7018 - Drug Profile
- KD-025 - Drug Profile
- lebrikizumab - Drug Profile
- LT-0011 - Drug Profile
- LTI-03 - Drug Profile
- MMI-0100 - Drug Profile
- MOR-107 - Drug Profile
- MSM-735 - Drug Profile
- NAS-911 - Drug Profile
- Neumomir - Drug Profile
- OLX-201 - Drug Profile
- P-013 - Drug Profile
- PBF-1129 - Drug Profile
- PBI-4050 - Drug Profile
- PBI-4425 - Drug Profile
- pirfenidone - Drug Profile
- PRM-151 - Drug Profile
- PUR-1500 - Drug Profile
- PXS-4820 - Drug Profile
- RBM-005 - Drug Profile
- RBM-006 - Drug Profile
- Refacell-IPF - Drug Profile
- RP-6503 - Drug Profile
- RT-234 - Drug Profile
- SAR-156597 - Drug Profile
- SD-560 - Drug Profile
- simtuzumab - Drug Profile
- Small Molecule for Idiopathic Pulmonary Fibrosis - Drug Profile
- Small Molecule for Idiopathic Pulmonary Fibrosis - Drug Profile
- Small Molecules for COPD and IPF - Drug Profile
- Small Molecules to Antagonize Integrin Alpha V for Idiopathic Pulmonary Fibrosis - Drug Profile
- Small Molecules to Inhibit LOXL2 for Oncology and Idiopathic Pulmonary Fibrosis - Drug Profile
- Small Molecules to Inhibit PTPN13 for Idiopathic Pulmonary Fibrosis - Drug Profile
- Small Molecules to Inhibit USP34 for Idiopathic Pulmonary Fibrosis - Drug Profile
- SPL-334 - Drug Profile
- Stem Cell Therapy for Idiopathic Lung Fibrosis - Drug Profile
- Stem Cell Therapy for Idiopathic Pulmonary Fibrosis - Drug Profile
- Synthetic Peptide to Antagonize CD168 for Respiratory, Dermatology, Oncology and Musculoskeletal Disorders - Drug Profile
- TD-139 - Drug Profile
- tipelukast - Drug Profile
- tralokinumab - Drug Profile
- YH-siRNA1 - Drug Profile
- ZL-2101 - Drug Profile
- ZL-2102 - Drug Profile
- Idiopathic Pulmonary Fibrosis - Recent Pipeline Updates
- Idiopathic Pulmonary Fibrosis - Dormant Projects
- Idiopathic Pulmonary Fibrosis - Discontinued Products
- Idiopathic Pulmonary Fibrosis - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products under Development for Idiopathic Pulmonary Fibrosis, H2 2015
- Number of Products under Development for Idiopathic Pulmonary Fibrosis - Comparative Analysis, H2 2015
- Number of Products under Development by Companies, H2 2015
- Number of Products under Development by Companies, H2 2015 (Contd..1)
- Number of Products under Development by Companies, H2 2015 (Contd..2)
- Number of Products under Development by Companies, H2 2015 (Contd..3)
- Number of Products under Investigation by Universities/Institutes, H2 2015
- Comparative Analysis by Clinical Stage Development, H2 2015
- Comparative Analysis by Early Stage Development, H2 2015
- Comparative Analysis by Unknown Stage Development, H2 2015
- Products under Development by Companies, H2 2015
- Products under Development by Companies, H2 2015 (Contd..1)
- Products under Development by Companies, H2 2015 (Contd..2)
- Products under Development by Companies, H2 2015 (Contd..3)
- Products under Development by Companies, H2 2015 (Contd..4)
- Products under Investigation by Universities/Institutes, H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by AdAlta Pty Ltd., H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by Aeolus Pharmaceuticals, Inc., H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by Afferent Pharmaceuticals, Inc., H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by AnaMar AB, H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by Biogen, Inc., H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by Bioneer Corporation, H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by BiOrion Technologies B.V., H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by Bristol-Myers Squibb Company, H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by Carolus Therapeutics, Inc., H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by Celgene Corporation, H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by Compugen Ltd., H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by FibroGen, Inc., H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by Galapagos NV, H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by GenKyoTex S.A., H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by Gilead Sciences, Inc., H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by Global Blood Therapeutics, Inc., H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by HanAll Biopharma Co., Ltd., H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by HEC Pharm Co., Ltd., H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by Histocell S.L., H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by iBio, Inc., H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by ImmuneWorks, LLC, H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by Inventiva SAS, H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by Isarna Therapeutics GmbH, H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by Kadmon Corporation, LLC, H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by Kasiak Research Private Limited, H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by LTT Bio-Pharma Co., Ltd., H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by MedImmune, LLC, H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by Moerae Matrix, Inc., H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by MorphoSys AG, H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by MSM Protein Technologies, Inc., H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by Pacific Therapeutics Ltd., H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by Pharmaxis Limited, H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by Progenra, Inc., H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by Promedior, Inc., H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by ProMetic Life Sciences Inc., H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by Pulmatrix, Inc., H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by Respira Therapeutics, Inc., H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by Rhizen Pharmaceuticals SA, H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by Ribomic Inc., H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by Sanofi, H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015
- Idiopathic Pulmonary Fibrosis - Pipeline by Yuhan Corporation, H2 2015
- Assessment by Monotherapy Products, H2 2015
- Assessment by Combination Products, H2 2015
- Number of Products by Stage and Target, H2 2015
- Number of Products by Stage and Mechanism of Action, H2 2015
- Number of Products by Stage and Route of Administration, H2 2015
- Number of Products by Stage and Molecule Type, H2 2015
- Idiopathic Pulmonary Fibrosis Therapeutics - Recent Pipeline Updates, H2 2015
- Idiopathic Pulmonary Fibrosis - Dormant Projects, H2 2015
- Idiopathic Pulmonary Fibrosis - Dormant Projects (Contd..1), H2 2015
- Idiopathic Pulmonary Fibrosis - Dormant Projects (Contd..2), H2 2015
- Idiopathic Pulmonary Fibrosis - Discontinued Products, H2 2015
- List of Figures
- Number of Products under Development for Idiopathic Pulmonary Fibrosis, H2 2015
- Number of Products under Development for Idiopathic Pulmonary Fibrosis - Comparative Analysis, H2 2015
- Number of Products under Development by Companies, H2 2015
- Number of Products under Investigation by Universities/Institutes, H2 2015
- Comparative Analysis by Clinical Stage Development, H2 2015
- Comparative Analysis by Early Stage Products, H2 2015
- Assessment by Monotherapy Products, H2 2015
- Number of Products by Top 10 Targets, H2 2015
- Number of Products by Stage and Top 10 Targets, H2 2015
- Number of Products by Top 10 Mechanism of Actions, H2 2015
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
- Number of Products by Routes of Administration, H2 2015
- Number of Products by Stage and Routes of Administration, H2 2015
- Number of Products by Top 10 Molecule Types, H2 2015
- Number of Products by Stage and Top 10 Molecule Types, H2 2015
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook